Amicus, Thermo Fisher’s Brammer Bio Partner on Gene Therapy Manufacturing

Amicus Therapeutics will address clinical and commercial supply needs for its intrathecal AAV Batten disease gene therapy programs by partnering with Thermo Fisher Scientific’s recently-acquired Brammer Bio.

Plant Virus Used as Cancer Immunotherapy Agent

Mice tumor free and protected from metastases after treatment

Aveo Signs BI on as Production Partner for Clinical-Stage mAb

Boehringer will take care of process development and clinical manufacturing of ficlatuzumab.

Scientists Develop Lentil-Shaped Lipid Vesicles that Target Drugs to Stenotic Vessels

Increased shear stress force within narrowed arteries cause vesicles to develop drug-leaching pores.

Antibacterial Pore-Punching Cellular Nanomachinery Filmed

One of the ways by which our immune systems attack and kill bacteria in the blood is by assembling protein complexes—think of them as...

Arsanis Halts Phase II Trial of Pneumonia Candidate ASN100

Company heeds recommendation of data review committee, which determined that the study was not likely to meet its primary endpoint, the proportion of patients who develop S. aureus pneumonia through 21 days after dosing

NOVEL STRATEGY FOR TREATMENT OF HIV AND OTHER VIRAL INFECTIONS

- GEN's Editor-in-Chief John Sterling interviews Stephen Becker, M.D., Chief Medical Officer, Koronis Pharmaceuticals

Promising Broad-Spectrum Antiviral Emerges for COVID-19 from Veteran SARS Lab

A recently described compound may prove to be a promising candidate in the fight against COVID-19. Its potency against multiple coronaviruses, therapeutic efficacy, and oral bioavailability all highlight its potential as an effective therapeutic. Here, we take a deep dive into why the compound, discovered by a SARS veteran, is garnering so much excitement as an effective antiviral against SARS-CoV-2 and other, future zoonotic coronaviruses.

Firms Ink CDx Antibody Imaging Deal

ImagineAb and MacroGenics inked a collaboration and commercialization agreement with MacroGenics focused on the development of an anti-CD3 clinical imaging product, and companion imaging agents for B7-H3, an immune regulatory target against which MacroGenics is developing therapeutics.

Aduro Licenses Cancer Immunotherapy from BioSante

Deal covers GVAX Pancreas and Prostate, development of which was previously halted.

Recently Featured

Scroll Up